Immunization, Hib3 in Euro area
Euro area: Immunization, Hib3 was 92.8% in 2024. ▲ Rising
Immunization, Hib3 in Euro area, 1990–2024
Source: WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/). Measured in % of children ages 12-23 months.
Analysis
In 2024, immunization, hib3 in Euro area stood at 92.8%.
The figure is down 1.2% over ten years.
Over the whole period, immunization, hib3 in Euro area peaked at 95.9% in 2012 and was at its lowest, 0.0%, in 1990.
Euro area ranks 8th of 43 groups on this measure, in the top quarter.
The long-run direction has been consistently rising across the 35 years of available data.
Immunization, Hib3 in Euro area, year by year
| Year | % of children ages 12-23 months | Change |
|---|---|---|
| 1990 | 0.0% | — |
| 1991 | 15.7% | — |
| 1992 | 19.9% | +26.5% |
| 1993 | 20.8% | +4.7% |
| 1994 | 21.1% | +1.4% |
| 1995 | 22.6% | +7.4% |
| 1996 | 23.7% | +4.7% |
| 1997 | 31.8% | +34.1% |
| 1998 | 62.6% | +96.9% |
| 1999 | 68.2% | +8.9% |
| 2000 | 79.2% | +16.1% |
| 2001 | 82.8% | +4.6% |
| 2002 | 86.9% | +4.9% |
| 2003 | 88.8% | +2.2% |
| 2004 | 91.9% | +3.5% |
| 2005 | 92.4% | +0.6% |
| 2006 | 93.3% | +1.0% |
| 2007 | 93.3% | -0.0% |
| 2008 | 93.4% | +0.1% |
| 2009 | 93.3% | -0.2% |
| 2010 | 95.0% | +1.9% |
| 2011 | 95.6% | +0.6% |
| 2012 | 95.9% | +0.4% |
| 2013 | 93.4% | -2.6% |
| 2014 | 93.9% | +0.5% |
| 2015 | 94.5% | +0.6% |
| 2016 | 93.8% | -0.7% |
| 2017 | 93.6% | -0.2% |
| 2018 | 93.6% | -0.1% |
| 2019 | 93.7% | +0.2% |
| 2020 | 94.0% | +0.2% |
| 2021 | 95.0% | +1.1% |
| 2022 | 92.9% | -2.2% |
| 2023 | 92.8% | -0.2% |
| 2024 | 92.8% | +0.0% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 1990s | 28.6% | 0.0% | 68.2% | 10 |
| 2000s | 89.5% | 79.2% | 93.4% | 10 |
| 2010s | 94.3% | 93.4% | 95.9% | 10 |
| 2020s | 93.5% | 92.8% | 95.0% | 5 |
More health data for Euro area
- Population ages 30-34, female, per capita 0.0286 units per person (2025)
- Population ages 35-39, male, annual growth rate 0.1709 % change on previous year (2025)
- Population ages 35-39, female, per capita 0.0309 units per person (2025)
- Population ages 35-39, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 35-39, female, annual growth rate -0.1844 % change on previous year (2025)
- Population ages 30-34, male, per capita 0.0298 units per person (2025)
- Population ages 30-34, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 30-34, male, annual growth rate -1.96 % change on previous year (2025)
- Population ages 25-29, female, per capita 0.027 units per person (2025)
- Population ages 25-29, male, annual growth rate 0.1302 % change on previous year (2025)
Frequently asked questions
- What is immunization, hib3 in Euro area?
- Immunization, hib3 in Euro area was 92.8% in 2024, according to WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).
- What is the highest immunization, hib3 recorded in Euro area?
- The highest recorded value was 95.9% in 2012.
- What is the lowest immunization, hib3 recorded in Euro area?
- The lowest recorded value was 0.0% in 1990.
- How does Euro area rank for immunization, hib3?
- Euro area ranks 8th out of 43 groups with data for 2024.
- Is immunization, hib3 rising or falling in Euro area?
- Over the last ten years it is down 1.2%. The long-run trend across the full record is rising.
- Where does this Euro area data come from?
- The figures come from WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as part of Immunization, Hib3 (% of children ages 12-23 months). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 35 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.